Associated Papers
Catalogue of Somatic Mutations in Cancer Database and Structural Modeling Analysis of CYP2D6 Mutations in Human Cancers.
Kuchinski K et al.
The Journal of Pharmacology and Experimental Therapeutics, 2024
The genetic landscape of major drug metabolizing cytochrome P450 genes-an updated analysis of population-scale sequencing data.
Zhou Y et al.
The Pharmacogenomics Journal, 2022
Cytochrome P450 2D6 and Parkinson's Disease: Polymorphism, Metabolic Role, Risk and Protection.
Ur Rasheed MS et al.
Neurochemical Research, 2017
CYP2D6 genotype and adjuvant tamoxifen: meta-analysis of heterogeneous study populations.
Province MA et al.
Clinical Pharmacology and Therapeutics, 2014
Evaluation of CYP2D6 and efficacy of tamoxifen and raloxifene in women treated for breast cancer chemoprevention: results from the NSABP P1 and P2 clinical trials.
Goetz MP et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research, 2011
Novel pathway analysis of genomic polymorphism-cancer risk interaction in the Breast Cancer Prevention Trial.
Dunn BK et al.
International Journal of Molecular Epidemiology and Genetics, 2010
Expression, purification, biochemical characterization, and comparative function of human cytochrome P450 2D6.1, 2D6.2, 2D6.10, and 2D6.17 allelic isoforms.
Yu A et al.
The Journal of Pharmacology and Experimental Therapeutics, 2002
Characterization of (+/-)-bufuralol hydroxylation activities in liver microsomes of Japanese and Caucasian subjects genotyped for CYP2D6.
Shimada T et al.
Pharmacogenetics, 2001
Low frequency of defective alleles of cytochrome P450 enzymes 2C19 and 2D6 in the Turkish population.
Aynacioglu AS et al.
Clinical Pharmacology and Therapeutics, 1999
Genetic polymorphisms of human N-acetyltransferase, cytochrome P450, glutathione-S-transferase, and epoxide hydrolase enzymes: relevance to xenobiotic metabolism and toxicity.
Wormhoudt LW et al.
Critical Reviews in Toxicology, 1999
Assessment of the predictive power of genotypes for the in-vivo catalytic function of CYP2D6 in a German population.
Griese EU et al.
Pharmacogenetics, 1998
A combination of mutations in the CYP2D6*17 (CYP2D6Z) allele causes alterations in enzyme function.
Oscarson M et al.
Molecular Pharmacology, 1997
Impact of P450 genetic polymorphism on the first-pass extraction of cardiovascular and neuroactive drugs.
Eichelbaum M et al.
Advanced Drug Delivery Reviews, 1997